

Dimitrios Vagiannis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9259555/publications.pdf>

Version: 2024-02-01

10
papers

123
citations

1307594

7
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

70
citing authors

#	ARTICLE	IF	CITATIONS
1	Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. <i>Molecular Pharmaceutics</i> , 2019, 16, 4436-4450.	4.6	22
2	Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme. <i>Cancers</i> , 2020, 12, 813.	3.7	20
3	Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme. <i>Biochemical Pharmacology</i> , 2020, 178, 114061.	4.4	16
4	Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. <i>Chemico-Biological Interactions</i> , 2021, 340, 109448.	4.0	16
5	Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. <i>Drug Metabolism and Disposition</i> , 2019, 47, 699-709.	3.3	15
6	Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo. <i>Biochemical Pharmacology</i> , 2022, 199, 115009.	4.4	10
7	Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. <i>Toxicology and Applied Pharmacology</i> , 2022, 434, 115823.	2.8	9
8	Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11936.	4.1	7
9	Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. <i>Toxicology and Applied Pharmacology</i> , 2022, 434, 115797.	2.8	4
10	ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112962.	5.6	4